Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis

Journal of the National Cancer Institute

Volumn 95, Issue 12, 2003, Pages 878-889

  Fu, Zheng ^a   Smith, Peter C ^a   Zhang, Lizhi ^a   Rubin, Mark A ^b   Dunn, Rodney L ^b   Yao, Zhi ^c   Keller, Eva T ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PROSTATE SPECIFIC ANTIGEN; RAF PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; EXPRESSION VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SAMPLE; AGED; ANIMAL; CANCER INVASION; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; MALE; METABOLISM; MIDDLE AGED; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROSTATE TUMOR; WESTERN BLOTTING;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, SCID; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RAF; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0038275924     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.12.878     Document Type: Article

References (36)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997 [published erratum appears in CA Cancer J Clin 1997;47:68]. CA Cancer J Clin 1997;47:5-27.
2. Bostwick DG. Staging prostate cancer-1997: current methods and limitations. Eur Urol 1997;32:2-14.
3. Welch DR, Rinker-Schaeffer CW. What defines a useful marker of metastasis in human cancer? J Natl Cancer Inst 1999;91:1351-3.
4. Yoshida BA, Sokoloff MM, Welch DR, Rinker-Schaeffer CW. Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst 2000;92:1717-30.
5. Dong JT, Suzuki H, Pin SS, Bova GS, Schalken JA, Isaacs WB, et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 1996;56:4387-90.
6. Yang X, Welch DR, Phillips KK, Weissman BE, Wei LL. KAI1, a putative marker for metastatic potential in human breast cancer. Cancer Lett 1997; 119:149-55.
7. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4.
8. Fu Z, Dozmorov I, Keller E. Osteoblasts produce soluble factors that induce a gene expression pattern in non-metastatic prostate cancer cells, similar to that found in bone metastatic prostate cancer cells. Prostate 2002;51:10-20.
9. Yeung K, Seitz T, Li S, Janosch P, McFerran B, Kaiser C, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999;401:173-7.
10. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer 1998;77:887-94.
11. Hori N, Chae KS, Murakawa K, Matoba R, Fukushima A, Okubo K, et al. A human cDNA sequence homologue of bovine phosphatidylethanol-amine-binding protein. Gene 1994;140:293-4.
12. Albini A. Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 1998;4:230-41.
13. Rashid MG, Sanda MG, Vallorosi CJ, Rios-Doria J, Rubin MA, Day ML. Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate. Cancer Res 2001; 61:489-92.
14. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002;287:1662-70.
15. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, et al. Rapid ("warm") autopsy study for procurement of metastatic prostate cancer. Clin Cancer Res 2000;6:1038-45.
16. Perrone EE, Theoharis C, Mucci NR, Hayasaka S, Taylor JM, Cooney KA, et al. Tissue microarray assessment of prostate cancer tumor proliferation in African-American and white men. J Natl Cancer Inst 2000;92: 937-9.
17. Maeda H, Segawa T, Kamoto T, Yoshida H, Kakizuka A, Ogawa O, et al. Rapid detection of candidate metastatic foci in the orthotopic inoculation model of androgen-sensitive prostate cancer cells introduced with green fluorescent protein. Prostate 2000;45:335-40.
18. Denhardt DT. Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Crit Rev Oncog 1996;7:261-91.
19. Sebolt-Leopold JS. Development of anticancer drugs targeting the MAP kinase pathway. Oncogene 2000;19:6594-9.
20. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77:841-52.
21. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265:966-70.
22. Welch DR, Sakamaki T, Pioquinto R, Leonard TO, Goldberg SF, Hon Q, et al. Transfection of constitutively active mitogen-activated protein/extracellular signal-regulated kinase kinase confers tumorigenic and metastatic potentials to NIH3T3 cells. Cancer Res 2000;60:1552-6.
23. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ra1-specific guanine exchange factor pathways. Mol Cell Biol 2001;21:5958-69.
24. Yu M, Leav BA, Leav I, Merk FB, Wolfe HJ, Ho SM. Early alterations in ras protooncogene mRNA expression in testosterone and estradiol-17 beta induced prostatic dysplasia of noble rats. Lab Invest 1993;68:33-44.
25. Leav I, Galluzzi CM, Ziar J, Stork PJ, Ho SM, Loda M. Mitogen-activated protein kinase and mitogen-activated kinase phosphatase-1 expression in the Noble rat model of sex hormone-induced prostatic dysplasia and carcinoma. Lab Invest 1996;75:361-70.
26. Kaplan PJ, Leav I, Greenwood J, Kwan PW, Ho SM. Involvement of transforming growth factor alpha (TGFalpha) and epidermal growth factor receptor (EGFR) in sex hormone-induced prostatic dysplasia and the growth of an androgen-independent transplantable carcinoma of the prostate. Carcinogenesis 1996;17:2571-9.
27. Price DT, Rocca GD, Guo C, Ballo MS, Schwinn DA, Luttrell LM. Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 1999;162:1537-42.
28. Brunet A, Pages G, Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 1994;9:3379-87.
29. Ichikawa T, Hosoki S, Suzuki H, Akakura K, Igarashi T, Furuya Y, et al. Mapping of metastasis suppressor genes for prostate cancer by microcell-mediated chromosome transfer. Asian J Androl 2000;2:167-71.
30. Deloukas P, Schuler GD, Gyapay G, Beasley EM, Soderlund C, Rodriguez-Tome P, et al. A physical map of 30,000 human genes. Science 1998;282: 744-6.
31. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001;11:S37-43.
32. Chung AS, Yoon SO, Park SJ, Yun CH. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003;36: 128-37.
33. Itoh Y, Nagase H. Matrix metalloproteinases in cancer. Essays Biochem 2002;38:21-36.
34. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94:17-25.
35. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-52.
36. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.